← All trials
NCT05983250
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Mar 31, 2027
- Completion date
- Jul 31, 2027
- First posted
- Aug 9, 2023
- Last posted
- Sep 5, 2023
- Enrollment
- 152
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tenax Therapeutics, Inc.Lead sponsor
- Medpace, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.